Bayer/Onyx's regorafenib looks positive in latest Phase III results for GIST
This article was originally published in Scrip
Executive Summary
Bayer HealthCare and Onyx Pharmaceuticals released a small glimpse of the positive results from the Phase III GRID clinical trial for regorafenib (BAY 73-4506) on 3 April, noting only that the compound met the primary endpoint of statistically significant improvement in progression-free survival for metastatic gastrointestinal stromal tumours (GIST).